



(UEN/Company Registration No. 201228542D)
(Incorporated with limited liability in Singapore)

ANNOUNCEMENT

UPDATE AND UPSIZE OF MULTICURRENCY DEBT ISSUANCE PROGRAMME FROM S\$1,500,000,000 TO S\$3,000,000,000

STT GDC Pte. Ltd. (the “**Issuer**”) wishes to announce that it has (i) updated its S\$1,500,000,000 multicurrency debt issuance programme (the “**Original Programme**”) established on 9 September 2019 (the “**Update**”); (ii) increased the maximum aggregate principal amount of notes (the “**Notes**”) and perpetual securities (the “**Securities**” and, together with the Notes, the “**Instruments**”) which may be issued under the Original Programme from S\$1,500,000,000 to S\$3,000,000,000 (the “**Increase**”); and (iii) with effect from 22 November 2024 (the “**Effective Date**”), made certain amendments to the Singapore Law Trust Deed and the English Law Trust Deed, each dated 9 September 2019 and made between the Issuer and DB International Trust (Singapore) Limited (the “**Amendments**”, and the Original Programme following the Update, the Increase and the Amendments, the “**Amended Programme**”). DBS Bank Ltd., Standard Chartered Bank (Singapore) Limited and United Overseas Bank Limited remain appointed as the arrangers and the dealers under the Amended Programme.

In connection with the Amended Programme, the Issuer has issued an updated offering circular dated 22 November 2024 (the “**Offering Circular**”).

The Amendments are made in respect of Instruments issued by the Issuer on or after the Effective Date (other than any Instruments issued so as to be consolidated and form a single series with any Instruments issued prior to the Effective Date) and do not affect the terms and conditions of the Instruments issued prior to the Effective Date (which remain in full force and effect).

Under the Amended Programme, the Issuer may, subject to compliance with all relevant laws, regulations and directives, from time to time issue Instruments denominated in any currency as agreed between the Issuer and the relevant dealer(s). The Instruments will be offered in Singapore to institutional investors (as defined in Section 4A of the Securities and Futures Act 2001 of Singapore, as modified or amended from time to time (the “**SFA**”)) pursuant to Section 274 of the SFA and accredited investors (as defined in Section 4A of the SFA) pursuant to and in accordance with the conditions specified in Section 275 of the SFA and (where applicable) Regulation 3 of the Securities and Futures (Classes of Investors) Regulations 2018.

Unless otherwise specified in the applicable pricing supplement, the net proceeds from the issue of each tranche of Instruments will be used by the Issuer for general corporate purposes, including but not limited to refinancing of existing borrowings and financing of investments, acquisitions, general working capital and/or capital expenditure of the Issuer and its subsidiaries.

Application has been made to the Singapore Exchange Securities Trading Limited (the “**SGX-ST**”) for permission to deal in, and for the listing and quotation of, any Instruments to be issued pursuant to the Amended Programme and which are agreed at or prior to the time of issue thereof to be so listed on the SGX-ST. Such permission will be granted when such Instruments have been admitted to the Official List of the SGX-ST. The SGX-ST assumes no responsibility for the correctness of any of the statements made or opinions expressed or reports contained herein. The approval in-principle from, and the admission of any Instruments to the Official List of, and the listing and quotation of any Instruments on, the SGX-ST are not to be taken as an indication of the merits of the Issuer, its subsidiaries, its associated companies, the Amended Programme or the Instruments.

Capitalised terms used but not defined herein shall have the same meaning as ascribed to them in the Offering Circular.

22 November 2024

*The Instruments have not been and will not be registered under the U.S. Securities Act of 1933, as amended (the “**Securities Act**”) or any U.S. State securities laws and may not be offered or sold in the United States unless an exemption from the registration requirements of the Securities Act is available and in accordance with all applicable securities laws of any state of the United States and any other jurisdiction. The Instruments are subject to certain restrictions on transfer. This announcement is for information only and does not constitute an invitation or offer to acquire, purchase or subscribe for securities. Neither this announcement nor any portion hereof may be reproduced, taken, sent or transmitted into the United States or to U.S. persons (as defined in Regulation S under the Securities Act) or into any jurisdiction where to do so is unlawful. Any failure to comply with these restrictions may constitute a violation of the United States securities law or the securities laws of any such other jurisdiction.*